Edition:
United States

Ligand Pharmaceuticals Inc (LGND.OQ)

LGND.OQ on NASDAQ Stock Exchange Global Market

135.81USD
21 Sep 2017
Change (% chg)

-- (--)
Prev Close
$135.81
Open
--
Day's High
--
Day's Low
--
Volume
--
Avg. Vol
94,248
52-wk High
$138.48
52-wk Low
$87.75

Chart for

About

Ligand Pharmaceuticals Incorporated (Ligand) is a biopharmaceutical company that focuses on developing and acquiring technologies that help pharmaceutical companies discover and develop medicines. The Company is involved in the development and licensing of biopharmaceutical assets. The Company employs research technologies, such... (more)

Overall

Beta: 1.02
Market Cap(Mil.): $2,859.27
Shares Outstanding(Mil.): 21.05
Dividend: --
Yield (%): --

Financials

  Industry Sector
P/E (TTM): -- 78.94 16.33
EPS (TTM): -- -- --
ROI: -- 2.84 14.66
ROE: -- 4.61 13.99

BRIEF-Ligand announces top-line results from Phase 2 study of LGD-6972 in patients with Type 2 diabetes

* Ligand announces top-line results from Phase 2 study of LGD-6972 in patients with Type 2 diabetes

Sep 05 2017

BRIEF-Ligand to receive $2 mln from WuXi Biologics for licensing clinical-stage anti-PD-1 antibody

* Ligand to receive $2 million from WuXi Biologics for licensing clinical-stage anti-PD-1 antibody discovered using the OmniAb technology

Aug 18 2017

BRIEF-Ligand Pharmaceuticals Q2 earnings per share $0.26

* Q2 earnings per share view $0.46 -- Thomson Reuters I/B/E/S

Aug 07 2017

BRIEF-Ligand enters into commercial license, supply agreement with Amgen

* Ligand enters into commercial license and supply agreement with Amgen for rights to use captisol in the formulation of AMG 330

Jul 17 2017

BRIEF-Ligand partner Melinta Therapeutics says FDA approves antibiotic Baxdela

* ligand’s partner melinta therapeutics announces u.s. Fda approval of baxdela™ (delafloxacin) for acute bacterial skin and skin structure infections (absssi)

Jun 20 2017

BRIEF-Ligand enters into worldwide Omniab platform license agreement with Surface Oncology

* Ligand enters into worldwide Omniab® platform license agreement with Surface Oncology

Jun 01 2017

BRIEF-Ligand enters into worldwide omniab platform license agreement with Xcella Biosciences

* Ligand enters into worldwide omniab® platform license agreement with xcella biosciences

May 30 2017

BRIEF-Ligand Pharmaceuticals enters into agreements with Interventional Analgesix

* On May 22, 2017, entered into a license agreement and a supply agreement with privately-held interventional analgesix, inc

May 23 2017

BRIEF-Ligand reports Q1 earnings per share $0.22

* Q1 earnings per share view $0.63 -- Thomson Reuters I/B/E/S

May 09 2017

BRIEF-Ligand enters commercial license and supply agreements with Marinus Pharmaceuticals for captisol-enabled Ganaxolone

* Ligand enters commercial license and supply agreements with Marinus Pharmaceuticals for captisol-enabled Ganaxolone

Apr 05 2017

Earnings vs. Estimates